BRCA Biomarkers
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.
FDA Approves FoundationOne Liquid CDx to Select BRCA-Mutated mCRPC Patients for Janssen's Akeega
The FDA expanded the label to include the blood-based sequencing test as well as the tissue-based CDx, which was already approved to select patients for Akeega.
UK NHS Launches Jewish BRCA Testing Program
The NHS Jewish BRCA Testing Program will provide free testing to anyone in England with Jewish ancestry.
The company, infamous and long derided in the genetic testing community for refusing to share BRCA1/2 variants, has decided to change its stance as part of a "strategic transformation."